Correction [0.03%]
改正措施
Published Erratum
Expert opinion on biological therapy. 2024 Sep;24(9):993. DOI:10.1080/14712598.2024.2390778 2024
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations [0.03%]
最新的治疗方法在轴向脊柱关节炎管理中的应用：进展和创新
Giuseppe Lopalco,Andrea Cito,Vincenzo Venerito et al.
Giuseppe Lopalco et al.
Introduction: Axial involvement in spondyloarthritis has significantly evolved from the original 1984 New York criteria for ankylosing spondylitis, leading to an improved understanding of axial spondyloarthritis (axSpA) a...
Correction [0.03%]
修正
Published Erratum
Expert opinion on biological therapy. 2024 Aug;24(8):i. DOI:10.1080/14712598.2024.2388405 2024
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19 [0.03%]
针对新冠病毒新突变株的单克隆抗体研发需考虑的问题
Arturo Casadevall,Scott McConnell,Daniele Focosi
Arturo Casadevall
Introduction: Monoclonal antibody (mAb) therapies proved safe and effective in preventing progression of COVID-19 to hospitalization, but most were eventually defeated by continued viral evolution. mAb combinations and th...
Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center [0.03%]
依那西普治疗儿童风湿病有效性和安全性的真实世界数据：单中心24个月回顾性研究
Ramazan Emre Yiğit,Kadir Ulu,Şengül Çağlayan et al.
Ramazan Emre Yiğit et al.
Objective: The aim of this study was to assess the efficacy and safety of etanercept (ETA) use in juvenile idiopathic arthritis (JIA). Methods: ...
The chimera of reaching a universal consensus on platelet-rich plasma treatment for knee osteoarthritis: a review of recent consensus statements and expert opinion [0.03%]
关于富血小板血浆治疗膝骨关节炎达成全球共识的海市蜃楼：最近共识声明和专家意见回顾
Elizaveta Kon,Giuseppe Anzillotti,Pietro Conte et al.
Elizaveta Kon et al.
Introduction: Osteoarthritis (OA) is a prevalent cause of disability worldwide, affecting millions and posing significant socioeconomic burdens. Various conservative measures like hyaluronic acid (HA) and platelet-rich pl...
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies [0.03%]
展望CD3 T细胞衔接剂双特异性抗体治疗血液系统恶性肿瘤的研究进展和发展方向
Daniel R Reed,Lawrence G Lum
Daniel R Reed
Introduction: Since the approval of the bispecific antibody blinatumomab in 2017 for the treatment of acute lymphoblastic leukemia in relapse, the development of numerous bispecific antibody constructs has dramatically ex...
Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases [0.03%]
针对神经系统疾病的腺相关病毒载体的实质内递送疗法
Shinichi Kumagai,Takeshi Nakajima,Shin-Ichi Muramatsu
Shinichi Kumagai
Introduction: In gene therapy with adeno-associated virus (AAV) vectors for diseases of the central nervous system, the vectors can be administered into blood vessels, cerebrospinal fluid space, or the brain parenchyma. W...
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis [0.03%]
优化抗肿瘤坏死因子α疗法治疗类风湿性关节炎的减停策略
Aliki I Venetsanopoulou,Paraskevi V Voulgari,Alexandros A Drosos
Aliki I Venetsanopoulou
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease that significantly impacts patients' quality of life. While treatment options have expanded over the years, including the introduction of tumor necro...
The potential for medical therapies to address fistulizing Crohn's disease: a state-of-the-art review [0.03%]
抗炎药物治疗克罗恩病的研究进展及目前存在的问题
Mohammad Shehab,Davide De Marco,Peter L Lakatos et al.
Mohammad Shehab et al.
Introduction: Crohn's disease (CD) is a chronic, relapsing immune mediated disease, which is one of the two major types of inflammatory bowel disease (IBD). Fistulizing CD poses a significant clinical challenge for physic...